Del.icio.us
Google
Yahoo MyWeb
Facebook
Ekos Overview
EKOS ® Corporation pioneered the development and the clinical application of microsonic technologies in medicine, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists and vascular surgeons at leading institutions across the nation use EKOS MicroSonic™ Accelerated Thrombolysis to provide safer, faster and more complete...More»
EKOS ® Corporation pioneered the development and the clinical application of microsonic technologies in medicine, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists and vascular surgeons at leading institutions across the nation use EKOS MicroSonic™ Accelerated Thrombolysis to provide safer, faster and more complete dissolution of thrombus. In 2008, the company introduced its 2nd generation EkoSonic™ Endovascular System with Rapid Pulse™ Modulation. The EkoSonic System is FDA cleared for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. It is currently used to treat patients with peripheral arterial occlusions (PAO) and deep vein thrombosis (DVT) and additional applications are being investigated.«Less
Key People
Management
Board of Directors
Funding
| Date | Type | Capital Amount | Post-Money Valuation | Investors |
|---|---|---|---|---|
| 03/27/2008 | Series C | 5M | Unknown |
|
| 01/2009 | Series D | 12.5M | Unknown |
Products
| Name: | EkoSonicTM Endovascular System with RPM |
| Product URL: | http://www.ekoscorp.com/EES_RPM.html |
| Description: | EkoSonic™ Endovascular System with Rapid Pulse™ Modulation In Laboratory in vitro testing, the EkoSonic system dissolved thrombus twice as fast as earlier EKOS systems - and four times faster than conventional catheter - directed thrombolysis. With no evidence of thrombus breakage. And no hemolysis. The EkoSonic™ Endovascular System is intended for the controlled and selective infusion of physician – specified fluids including thrombolytics, into the peripheral vasculature. The EkoSonic™ Endovascular System is also intended for the infusion of solutions into the Pulmonary Arteries. The Safety and effectiveness of the EkoSonic Endovascular System for thrombolytic therapy administration in pulmonary embolus have not been established. In particular, the ultrasound energy delivered by the EkoSonic System is not intended to be therapeutic, nor has it been cleared with an indication for thrombolysis in pulmonary emboli. With Rapid Pulse™ Modulation The innovation behind this breakthrough is EKOS Rapid Pulse™ Modulation, which manipulates the amplitude and duration of the microsonic energy released into the clot to optimize its impact. In laboratory tests with identical samples, Rapid Pulse Modulation demonstrated greater clot permeability and drug penetration, resulting in accelerated dissolution. |
Competitors
Profile
OpinionsRelated Companies
User Opinions
Bulls vs. Bears (0)
| Bullish Opinions (0) | ||||
|---|---|---|---|---|
| Be the first to tell us why they are destined to succeed | ||||
| Bearish Opinions (0) | ||||
|---|---|---|---|---|
| Be the first to tell us why they are destined to stumble. | ||||
Discussions (0)
Start a New Discussion
Opinion Poll
View All Opinions »
Web Metrics
View All Web Metrics »
| Alexa Rank: | n/a |  |
n/a |
| Yahoo Search Results: | n/a | ||
News & Blogs
View All News »- Latest
- Most Popular
- Submit a Story »
In First Entry in Top Survey, Dimensional Insight Is Number One for BI
Oct 24, 2011 - 0 comments
Report: Ekos Gets $12.5M
Jan 30, 2009 - 0 comments
Ekos on Twitter
Twitter Search »Discussions
View All Discussions »There are no discussions right now.
Recent Contributors
There are no recent contributors to this company.
Related Jobs
loading...